ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Apr 22, 2021 13:00 JST
Source:
Avance Clinical
Avance Clinical Invited to Present "Decentralized Trials - No Going Back" for Oracle Health Sciences Connect
ADELAIDE, AUS, Apr 22, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference.
Title: Decentralized Trials - No Going Back
Link:
https://www.oracle.com/in/industries/life-sciences/health-sciences-connect/sessions/
Time: 23 April, 2021 - 3.05 pm (Australia/Adelaide ACST).
Avance Clinical CEO Yvonne Lungershausen, shared the company's insights on the future of Decentralized Clinical Trials (DCTs) and the technology and patient factors that will determine success. Avance Clinical uses the full range of eClincial technologies to support clients wanting DCTs or a site-based approach while still leveraging advance technology including ePro, eSource and eConsent.
"DCTs are fast becoming the new norm and this is an incredible opportunity for the drug development sector as well as the diverse and remote patient populations that will now have access to clinical trials," said Lungershausen.
"The pandemic has been the catalyst in speeding up the adoption of decentralised clinical trial methods, as people stopped participating in trials and visiting clinics. Trials have stalled putting lives and significant investments at risk."
Yvonne Lungershausen said there are considerable benefits to DCT's including:
- Reduce the scheduling and travel burden on patients - providing care from the comfort of the patient's home.
- Connecting patients to trials on a global scale - patients that were otherwise inaccessible under more traditional trial protocols are now available.
And she said challenges include:
- Missed human-to-human contact and continuity of patient care
- Investigational product distribution to more remote destinations
- Oversight of compliance and study procedures in the patient's home
The presentation also covers advances in artificial intelligence (AI), machine learning, cloud computing and blood self-collection devices which are all revolutionising the decentralized clinical trial process.
- Wearable devices are demonstrating enormous potential whether worn as a wrist strap or an adhesive patch on the body. AI-embedded capabilities allow these devices to measure a patient's heart rate or metabolism remotely. Linked to the cloud through secure networks, clinicians can receive and analyse the data real-time.
- Video calling and electronic reminders, can improve patient compliance in trials - prompting participants to take their medication at the right time or to record in their electronic diary development.
- Technologies are developing to allow patient-centric sampling (self-collection of specimens) with devices that require the use of a lancet and finger prick whereas others do not, making clinical trials even more convenient.
Take the Quiz - Test your Knowledge about Australian Clinical Trials here:
https://www.surveymonkey.com/r/Australian-Clinical-Trials
About Avance Clinical
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field. Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Learn more at
http://www.avancecro.com
.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5-6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Media Contact:
media@avancecro.com
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Fujitsu Japan and Juntendo University launch joint research for disaster-resilient, digital medical system
Jun 03, 2024 11:02 JST
Mitsubishi Power to Supply Technology to Support Brazil's Largest Reliability Project
May 31, 2024 17:09 JST
Team HRC Participation in the Suzuka 8 Hours Endurance Road Race 45th Tournament
May 31, 2024 14:59 JST
DOCOMO Launches Japan's First Demonstration Experiment of Self-powered Hydropower Base Station
May 30, 2024 14:30 JST
Fujitsu leverages data and AI to enable Panasonic EW's resilient supply chain management
May 29, 2024 15:27 JST
Hydrogen Engine Generator Set Ready for In-house Evaluation
May 29, 2024 13:53 JST
Hitachi and Google Cloud Announce Strategic Partnership to Accelerate Innovation and Productivity with Generative AI
May 29, 2024 12:38 JST
Japanese Consortium Achieves World's First Demonstration of 5G Communication from Altitude of 4km Using 38GHz Band
May 29, 2024 11:44 JST
Hitachi High-Tech Launches the SU3900SE and SU3800SE Series High-Resolution Schottky Field Emission Scanning Electron Microscopes Allowing Observation of Large and Heavy Samples at the Nano Level
May 29, 2024 11:30 JST
Celonis and NEC begin Proof of Concept Integrating Generative AI and Process Intelligence
May 28, 2024 20:20 JST
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
May 28, 2024 15:19 JST
Roche and Hitachi High-Tech extend their long-standing partnership
May 28, 2024 12:53 JST
Subaru, Toyota, and Mazda Commit to New Engine Development for the Electrification Era, Toward Carbon Neutrality
May 28, 2024 12:45 JST
Fujitsu unveils 1FINITY T250, an optical transmission solution that enables new connectivity services to achieve IOWN initiative
May 28, 2024 10:45 JST
Idemitsu Kosan, ENEOS, Toyota, and MHI Commence Study toward Introduction and Spread of Carbon-Neutral Fuels for Automobiles
May 27, 2024 13:35 JST
Toyota: Evolved Liquid Hydrogen-Powered GR Corolla to Participate in Super Taikyu Fuji 24 Hours Race
May 24, 2024 16:19 JST
Hitachi Energy's HVDC technology to power Marinus Link, a key step toward Australia's Net Zero ambitions
May 24, 2024 14:39 JST
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
May 23, 2024 18:07 JST
MHI Thermal Systems Receives JSRAE Technology Award for "e-3D Scroll" Compressor
May 23, 2024 16:01 JST
NEC X Invests in Agtech Startup Verdi, Integrates AI-Powered Platform with NEC's Cropscope Smart Farming Initiative
May 23, 2024 11:20 JST
More Latest Release >>
Related Release
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical
May 31 2024 16:00 JST
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
May 08 2024 09:00 JST
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
April 19 2024 16:00 JST
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
March 28 2024 14:42 JST
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
February 28 2024 08:00 JST
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
January 12 2024 16:00 JST
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
Avance Clinical Joins Global Health Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies
May 25 2023 09:00 JST
Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023
April 18 2023 11:00 JST
More Press release >>